Search PubMed⌕ Search

Biomedical subjects

I Holló

Publications and source records attributed to I Holló.

14 recordsLinked to original sources
PubMed1992

[Treatment of postmenopausal osteoporosis with low doses of calcitonin and a calcitonin-anabolic combination].

Menopausal osteoporotic women (age: 49-69, mean: 59.5 years) with crush fractures of the spine were treated with low doses of calcitonin (Miacalcic, 350 U/month), or with calcitonin + anabolic steroid (Retabolil, 50 mg/month). Efficacy of the therapy was controlled by single foton absorptiometry of midshaft and distal radius, by X-ray morphometry and by registering new crush fractures of the spine. Calcitonin monotherapy stopped further bone loss for two years, but at the end of the third year both absorptiometric values, as well as the radiomorphometrical index of the lumbar spine decreased significantly. In patients on calcitonin+anabolic steroid the decrease was just significant and only at radius midshaft, while at the other measured sites it was not. Two new crush fractures per 1396 patient-months occurred. Intermittent administration of low-dose calcitonin, especially together with an anabolic steroid seems to be a safe and effective therapy in established osteoporosis.

Aged↗
PubMed1992

[Spinal and appendicular osteoporosis in streak gonad syndrome. Photon absorptiometric and roentgen-morphometric studies].

Patterns of bone loss in the axial and the appendicular skeleton were studied in 48 women with streak gonad syndrome (age: between 14-38 years, mean: 25.5 years). Bone mineral content was measured in vivo at the lumbar spine and right femoral neck by dual photon absorptiometry and at the midradius and distal radius by single photon absorptiometry. The bone mineral status of 20 patients was evaluated by radiomorphometrical indices of the metacarpals, femorals and lumbar spine, too. Mean bone mineral content and radiomorphometrical indices were significantly lower in patients with streak gonad syndrome than in age-matched normal subjects at all three scanning sites. The patients lost cortical and trabecular bone mineral content at the same rate, suggesting that bone loss in streak gonad syndrome is a generalized phenomenon. In spite of serious bone loss osteoporotic fractures were not observed in the patients, in contrast to patients with pathological post-menopausal osteoporosis having equal degree of bone deficiency. The authors did not find any relationship between the occurrence of osteoporosis and the karyotype of the patients. It is suggested that the osteoporosis in streak gonad syndrome--at least after puberty--is a consequence of gonadal hormone deficiency.

Absorptiometry, Photon↗
PubMed1992

Three-year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine.

Forty-five postmenopausal osteoporotic women with at least one osteoporotic vertebral crush fracture were randomized into three treatment groups. Each patient was on calcitonin, 50 U, on alternate days for 2 weeks monthly (350 U/month), and 500 mg/day oral calcium supplementation. In group II, this therapy was supplemented with phosphate (750 mg/day), and in group III, norandrostenolone decanoate (50 mg/month) was added to the calcitonin+calcium therapy. Bone mineral content, by single photon absorptiometry, of the radius midshaft and distal site (3 cm), as well as the lumbar and metacarpal radiomorphometrical indices were estimated seminannually. The therapeutic trial lasted 36 months except in the phosphate supplementation group, where, due to unfavorable results, treatment was discontinued after 24 months. Calcitonin practically prevented further bone loss for 24 months even in this relatively small and intermittent dosage. Phosphate supplementation was without benefit; however, according to the majority of the examined parameters, combination of calcitonin with the anabolic steroid norandrostenolone decanoate extended efficacy up to 36 months. This latter combination seems to be a promising, relatively inexpensive therapeutic regimen in the treatment of established postmenopausal osteoporosis.

Aged↗
PubMed1979

Influence of heavy smoking upon the bone mineral content of the radius of the aged and effect of tobacco smoke on the sensitivity to calcitonin of rats.

Using Norland-Cameron Bone Mineral Analyzer BMA 178 Type, it has been found that bone mineral content of the radius is considerably less in male heavy smokers aged 61 to 75 and 76 to 90, then in nonsmokers with similar age. Less difference was found within the group of 61 to 75 year old women. Furthermore, also it has been pointed out that the sensitivity to calcitonin of rats inhaling tobacco smoke is considerably less, than that of control rats. It is possible that smoking promotes the decrease in mineral content of bones i.e. the aggravation of osteoporosis, by the means of calcitonin resistance. The authors recommend tobacco abstinence to patients with osteoporosis and to persons who are particularly endangered by osteoporosis (e.g. in menopause, in post-gastrectomic state ect.).

Age Factors↗
PubMed1978

Effect of intravenous calcium load on the serum calcium level in postmenopausal osteoporosis (a study of the pathogenesis, and diagnostic use of the test).

Analysis of calcium tolerance in suggested to represent a valuable diagnostic aid in osteoporosis, particulary in the menopause. The serum calcium level was found to exceed 11.0 mg/dl 60 min after the intravenous injection of 3.6 mg per kg body weight of Ca++ in all patients with osteoporosis, while the level was normal at that point of time in every subject without osteoporosis, including patients with bone disease other than osteoporosis. Administration of norandrosterone decanoate or dehydroepinandrosterone to patients with menopausal osteoporosis resulted in normalization of the post-load hypercalcaemia. Calcium tolerance of menopausal patients without osteoporosis was not affected by dehydroepiandrosterone.

Calcium↗
PubMed1978

Bone mineral content of the healthy aged.

Using Norland-Cameron photon-absorption technique, bone mineral content of 436 healthy aged was measured and compared with that of 198 healthy, aged 21-50. Bone mineral content of postmenopausal females decreased continuously with age and bone mineral content of males began to decrease at age over 70. Bone width and menopausal age seemed to be important factors influencing bone mineral content, but previous physical activity seemed to have no effect on the bone mineral content of the aged.

Aged↗
PubMed1978

Influence of methyl xanthine treatment on calcitonin effect.

The presented results clearly demonstrate that theophylline, caffeine and theobromine have a blocking action on calcitonin effect as determined by the elevation of serum calcium level, although different degree of potency was found with each drugs. There is no difference in respect of the serum calcium elevation after a single dose of methyl xanthines or after a 9-10 day lasting treatment. The castration had no additional enhancing effect of the calcitonin resistance of methyl xanthine treated animals. The administration of androgens simultaneously with the methyl xanthine treatment failed to produce improvement of calcitonin sensitivty preventing the elevation of serum calcium after calcitonin injection. So the calcitonin resistance of methyl xanthine treated animals appears to be different to the calcitonin resistance of sex hormone deprived conditions because the latter could be abolished by androgen administration. Theophylline treatment resulted in a slightly but significantly elevated serum calcium comparing to controls without exogeneous calcitonin. This magnitude of elevation remains between the normocalcaemic limits.

Androgens↗
PubMed1977

Osteopenia.

Explore the source record for details and available documents.

Calcitonin↗
PubMed1977

Effect of aminoglutethimide on calcitonin sensitivity.

Studying the influence of aminoglutethimide treatment on calcitonin sensitivity, serum calcium levels were measured in normal rats, aminoglutethimide treated rats, adrenalectomized and castrated rats, following i.v. injection of porcine calcitonin. The aminoglutethimide administration caused a more distinct calcitonin resistance than surgical sex hormone deprivation. It was found that castration in most of experiments failed to enhance calcitonin resistance in aminoglutethimide treated animals. The aminoglutethimide administration may influence the steroid synthesis of adrenals, accessory adrenals and testes too. Results obtained with castrated, aminoglutethimide plus dehydroepiandrosterone treated and castrated, aminoglutethimide plus epiandrosterone treated rats affirm the earlier observations, i.e. in state of sex hormone deficiency the exogeneous androgens have an enhancing or restoring effect on calcitonin sensitivity.

Adrenal Cortex Hormones↗
PubMed1975

Postmenopausal osteoporosis: the effect of parathormone and large dose vitamin D3 on the serum calcium level in sex hormone deficient rats.

Rats deprived of adrenal and gonadel sex hormones are more sensitive than normal rats to the hypercalcaemic (osteolytic) effect of parathormone and toxic doses of vitamin D3. It is suggested that sex hormone deficiency and the consecutive decrease of calcitonin sensitivity in postmenopausal osteoporosis makes the patients unprotected against factors inducing increased bone resorption, and this leads over the years of osteoporosis.

Adrenalectomy↗